Benign prostatic hyperplasia (BPH) or prostate gland enlargement is caused due to urinary tract infections, bladder or kidney stones, prostatitis, urethral stricture, bladder or prostate cancer, and scarring in the bladder neck caused due to previous surgeries. The common signs and symptoms of BPH include frequent urination, nocturia, difficulty in initiating urination, dribble at the end of urination, and inability to empty the bladder. This disease is highly prevalent among men above the age of 40 years. Nearly one-third of the male population experience moderate-to-severe symptoms of BPH by 60 years of age.

Browse In-depth Benign Prostatic Hyperplasia Treatment Market Revenue Forecast Report-https://www.psmarketresearch.com/market-analysis/benign-prostatic-h...

As elderly men are highly susceptible to this urinary tract disease, a boom in the geriatric population will drive the BPH treatment market growth during the forecast period (2021–2030). The market was valued at $10 billion in 2020 and it is projected to generate around $17 billion revenue by 2030. According to the World Ageing Population 2020 report, the population of individuals aged 65 years or more will rise from 727 million in 2020 to over 1.5 billion by 2050.

The type segment of the BPH treatment market is bifurcated into surgical treatment and drug treatment. Of these, the drug treatment category accounted for the larger market share in 2020, due to the extensive use of medicines for managing and treating BPH at the sub-acute and acute levels. As medicated drugs are prescribed for post-operative treatment as well, the sales of drugs exceed that of surgical devices. This category is further classified into alpha blockers, 5-alpha reductase inhibitors, and others.

Whereas, the Asia-Pacific (APAC) BPH treatment market is expected to showcase the fastest growth during the forecast period, due to the growing aging population, rising cases of BPH and associated disorders, and mounting investments being made in the healthcare sector in the region. As per the United Nations Population Fund (UNFPA), one in every four people in APAC would be above 60 years of age, by 2050. As BPH is extremely common among people above 50 years of age, the surging population of the elderly will give an impetus to the market growth in the region in the forecast years.

Therefore, the booming geriatric population and the rising cases of BPH will create a huge requirement for BPH treatment drugs and devices in the upcoming years.